149 related articles for article (PubMed ID: 25757921)
1. Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma.
Nagata M; Ishiwata Y; Takahashi Y; Takahashi H; Saito K; Fujii Y; Kihara K; Yasuhara M
Biol Pharm Bull; 2015; 38(3):402-10. PubMed ID: 25757921
[TBL] [Abstract][Full Text] [Related]
2. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Khosravan R; Motzer RJ; Fumagalli E; Rini BI
Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
Miura Y; Imamura CK; Fukunaga K; Katsuyama Y; Suyama K; Okaneya T; Mushiroda T; Ando Y; Takano T; Tanigawara Y
BMC Cancer; 2014 Dec; 14():964. PubMed ID: 25515134
[TBL] [Abstract][Full Text] [Related]
6. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.
Kato R; Kato Y; Matsuura T; Kanehira M; Takata R; Obara W
BMC Cancer; 2017 Mar; 17(1):214. PubMed ID: 28335742
[TBL] [Abstract][Full Text] [Related]
8. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
9. [Successful Management by Immunoglobulin for Sunitinib-Induced Thrombocytopenia in a Patient with Advanced Metastatic Renal Cell Carcinoma].
Okazaki S; Hori J; Watanabe M; Hashizume K; Kobayashi S; Azumi M; Kita M; Iwata T; Matsumoto S; Kakizaki H
Hinyokika Kiyo; 2016 Feb; 62(2):73-6. PubMed ID: 27018409
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
13. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
[TBL] [Abstract][Full Text] [Related]
14. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC
Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
[TBL] [Abstract][Full Text] [Related]
18. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
20. Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma.
Takasaki S; Kawasaki Y; Kikuchi M; Tanaka M; Suzuka M; Noda A; Sato Y; Yamashita S; Mitsuzuka K; Saito H; Ito A; Yamaguchi H; Arai Y; Mano N
Int J Clin Oncol; 2018 Oct; 23(5):936-943. PubMed ID: 29860539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]